Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial

Blood

Volumn 99, Issue 8, 2002, Pages 2734-2739

  Duval, Michel ^{a,b,c,d,e,f,g,h,i,j}   Suciu, Stefan ^{a,b,c,d,e,f,g,h,i,j}   Ferster, Alina ^{a,b,c,d,e,f,g,h,i,j}   Rialland, Xavier ^{a,b,c,d,e,f,g,h,i,j}   Nelken, Brigitte ^{a,b,c,d,e,f,g,h,i,j}   Lutz, Patrick ^{a,b,c,d,e,f,g,h,i,j}   Benoit, Yves ^{a,b,c,d,e,f,g,h,i,j}   Robert, Alain ^{a,b,c,d,e,f,g,h,i,j}   Manel, Anne Marie ^{a,b,c,d,e,f,g,h,i,j}   Vilmer, Etienne ^{a,b,c,d,e,f,g,h,i,j}   Otten, Jacques ^{a,b,c,d,e,f,g,h,i,j}   Philippe, Noël ^{a,b,c,d,e,f,g,h,i,j}  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b EORTC DATA CENTER   (Belgium)

^c Centre Hospitalier Universitaire   (Belgium)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERWINIA ASPARGINASE; ERWINIASE; ESCHERICHIA COLI ASPARAGINASE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PARONAL; PREDNISOLONE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANAPHYLAXIS; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOSIS; TREATMENT FAILURE;

EID: 0037089437     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.8.2734     Document Type: Article

References (33)

1. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia
2. Fouragent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
3. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children
4. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
5. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia
6. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase
7. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone
8. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia
9. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia
10. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures
11. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia
12. Anaphylactold reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma
13. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
14. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia
15. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
16. A pilot study of intensive chemotherapy in poor prognosis relapsed acute lymphoblastic leukemia in childhood
17. The BFM relapse studies in childhood ALL: Concepts of two multicenter trials and results after 2 1/2 years
18. Reporting results of cancer treatment
19. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic
20. Value of high-dose Ara-C during interval therapy of a BFM-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the EORTC 58881 randomized phase III trial
21. The value of 6-MP i.v. during maintenance treatment in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: Results of the randomized phase III trial 58881 of EORTC Childhood Leukemia Cooperative Group
22. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized study
23. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations
24. Comparative pharmacokinetic studies of three asparaginase preparations
25. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
26. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols
27. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia
28. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia
29. Loss of activity of Erwinia asparaginase on repeat applications
30. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia
31. Pegylated asparaginase (Oncaspar™) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols